Related Experiment Video

Updated: Dec 13, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.4K

Angustoline Inhibited Esophageal Tumors Through Regulating LKB1/AMPK/ELAVL1/LPACT2 Pathway and Phospholipid

Huiying Li1, Cheng Zhang2, Min Zhang2

  • 1Key Laboratory of Quality and Safety Control for Milk and Dairy Products of Ministry of Agriculture and Rural Affairs, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, China.

Frontiers in Oncology
|August 1, 2020
PubMed

Insights

Angustoline, a natural product, inhibits esophageal cancer progression by activating LKB1/AMPK and suppressing ELAVL1/LPCAT2. This mechanism blocks phospholipid remodeling, offering a potential therapeutic strategy for esophageal tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Natural Products Chemistry

Background:

  • Esophageal cancer is a leading cause of cancer death globally, with unclear mechanisms of proliferation and metastasis.
  • Identifying novel therapeutic agents, particularly from natural products, is crucial for combating esophageal tumors.

Purpose of the Study:

  • To investigate the anti-cancer effects of angustoline on esophageal cancer cells and elucidate its underlying molecular mechanisms.
  • To identify key molecular targets and metabolic pathways involved in angustoline's action against esophageal tumors.

Main Methods:

  • Utilized esophageal cancer cell line KYSE450 for in vitro assays (viability, migration, invasion).
  • Performed lipidomic analysis on clinical esophageal cancer samples (tissue and plasma) to identify specific phospholipid metabolites.
  • Investigated the expression of LKB1/AMPK and ELAVL1/LPCAT2 pathways in tumor tissues and cells.
  • Validated angustoline's effects in a KYSE450 tumor-bearing mouse model.

Main Results:

  • Angustoline demonstrated inhibitory effects on esophageal cancer cell viability, migration, and invasion.
  • Identified specific phospholipid metabolites PC (16:0/18:1) and LPC (16:0) as potential biomarkers.
  • Angustoline was found to activate the LKB1/AMPK pathway and inhibit the ELAVL1/LPCAT2 pathway.
  • Demonstrated that angustoline blocks phospholipid remodeling from LPC (16:0) to PC (16:0/18:1) in esophageal tumors.

Conclusions:

  • Angustoline suppresses esophageal tumor growth and metastasis by modulating the LKB1/AMPK/ELAVL1/LPCAT2 signaling pathway.
  • This study reveals a novel mechanism involving phospholipid remodeling in esophageal cancer progression and angustoline's therapeutic potential.
Keywords:
AMPKELAVL1LKB1LPCAT2esophageal cancerlipidomics

More Related Videos

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

20.4K
An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.3K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
16.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K